5-Amino-1MQ Research:
NNMT Inhibitor & Metabolic Reprogramming
5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor. By blocking NNMT, it redirects the SAM methyl donor pool toward NAD⁺ biosynthesis, adipogenesis regulation, and epigenetic reprogramming — a novel metabolic research target.
What Is 5-Amino-1MQ?
5-Amino-1-methylquinolinium (5-Amino-1MQ) is a selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (vitamin B3), producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). NNMT is highly expressed in white adipose tissue, liver, and certain cancer types, and its overexpression is associated with obesity, metabolic syndrome, and cellular senescence in research models.
By inhibiting NNMT, 5-Amino-1MQ conserves the SAM methyl donor pool, redirects nicotinamide toward NAD⁺ biosynthesis via the Preiss-Handler pathway, and alters the cellular methylation landscape — affecting epigenetic marks, gene expression programs, and adipocyte differentiation. Lumen Peppers provides research-grade 5-Amino-1MQ for in vitro and preclinical laboratory investigation only.
Key Research Findings
5-Amino-1MQ research spans adipogenesis, NAD⁺ metabolism, epigenetic reprogramming, obesity models, and cellular senescence biology.
Anti-Adipogenic Activity
5-Amino-1MQ suppresses adipocyte differentiation in 3T3-L1 preadipocyte models, reducing lipid droplet accumulation, PPAR-γ expression, and adiponectin secretion. In HFD-fed mice, 5-Amino-1MQ reduces white adipose tissue mass by up to 7% over 4 weeks without altering food intake — consistent with NNMT-driven adipogenesis inhibition.
NAD⁺ Level Elevation
NNMT inhibition by 5-Amino-1MQ redirects nicotinamide from 1-MNA production toward the Preiss-Handler (NAMPT-NMNAT) and de novo NAD⁺ biosynthetic pathways. Cellular NAD⁺ levels increase 1.5–2× in adipocyte and hepatocyte models — activating SIRT1, SIRT3, and PARP enzymes that require NAD⁺ as co-substrate.
Epigenetic Reprogramming
By conserving the SAM methyl donor pool, NNMT inhibition maintains histone and DNA methylation levels. Reduced NNMT activity in adipose tissue normalizes H3K4me3 marks at genes regulating thermogenesis (UCP1, PRDM16) and lean adipose phenotype, converting white adipocyte gene expression profiles toward beige/brown adipocyte-like states.
Cellular Senescence Research
NNMT expression increases in senescent cells, where it drives the SASP (senescence-associated secretory phenotype) through epigenetic mechanisms. 5-Amino-1MQ treatment in senescent fibroblast cultures reduces p21, p16, and SASP markers (IL-6, IL-8, MMP-3) — making it a research tool for studying NNMT's role in the senescence epigenome.
Obesity Model Studies
In DIO (diet-induced obesity) mouse models, 5-Amino-1MQ administered in drinking water at 10 mg/kg/day reduces adiposity, improves insulin sensitivity (HOMA-IR), and lowers circulating free fatty acids without toxicity signals in published studies. These effects are attributed to combined NNMT inhibition in adipose tissue and liver.
NNMT as Cancer Research Target
NNMT overexpression in multiple cancer types (ovarian, breast, colorectal, glioma) is associated with tumor invasion, drug resistance, and poor prognosis. 5-Amino-1MQ reduces proliferation and migration in NNMT-overexpressing tumor cell lines — identifying NNMT as a metabolic vulnerability in cancer research models.
Proposed Mechanisms of Action
5-Amino-1MQ competitively inhibits NNMT by occupying the nicotinamide binding pocket, preventing SAM from donating its methyl group to nicotinamide. This preserves SAM for other methyltransferases (DNMT, PRMT, EHMT1/2) — elevating cellular methylation potential (SAM/SAH ratio) and reshaping the epigenetic landscape.
NNMT inhibition increases free nicotinamide availability, redirecting it through NAMPT (nicotinamide phosphoribosyltransferase) → NMNAT (nicotinamide mononucleotide adenylyltransferase) to generate NMN and then NAD⁺. Elevated NAD⁺ activates SIRT1 (nuclear gene regulation) and SIRT3 (mitochondrial deacetylase), driving metabolic reprogramming.
Elevated NAD⁺-driven SIRT1 activity deacetylates and represses PPAR-γ (master adipogenic transcription factor), reducing lipid droplet accumulation and adipocyte differentiation. SIRT1 also deacetylates PGC-1α, increasing mitochondrial biogenesis and fatty acid oxidation in adipocytes — contributing to the anti-adipogenic phenotype.
NNMT inhibition normalizes H3K4me3 methylation (a permissive chromatin mark) at thermogenic gene promoters (UCP1, PRDM16, CIDEA). This chromatin accessibility change shifts gene expression from white to beige adipocyte programs, increasing energy expenditure potential in adipose tissue research models.
In senescent cells, 5-Amino-1MQ reduces NNMT-driven H3K9 demethylation at SASP gene promoters, restoring repressive chromatin marks. Combined with SIRT1 activation (via NAD⁺ elevation), this reduces NF-κB-dependent SASP gene transcription — attenuating the paracrine inflammatory signaling of senescent cells.
Active Research Applications
Adipogenesis & Obesity
3T3-L1 differentiation assays, HFD mouse body composition, PPAR-γ/CEBPA expression, and lipid droplet quantification studies.
NAD⁺ Metabolism
Cellular NAD⁺/NADH ratio measurements, SIRT1/SIRT3 activity assays, and comparative studies with NMN and NR as NAD⁺ precursors.
Epigenetic Research
ChIP-seq for H3K4me3/H3K9me2 at adipogenic and thermogenic gene loci, DNMT activity assays, and methylation proteomics.
Senescence Biology
SASP quantification, p21/p16 expression, β-galactosidase staining, and NNMT inhibition effects on senescent cell inflammatory secretome.
Cancer Metabolism
NNMT-overexpressing cell line proliferation, invasion (Matrigel), and drug sensitivity studies using 5-Amino-1MQ as a metabolic inhibitor.
Drug Discovery
NNMT inhibitor SAR studies — 5-Amino-1MQ as reference compound for developing next-generation NNMT inhibitors with improved selectivity and bioavailability.
Protocol Notes for Researchers
5-Amino-1MQ — Research Grade ≥99%
Research-grade purity ≥99% · Third-party HPLC verified · Ships from the U.S.
All products sold by Lumen Peppers are intended exclusively for in vitro laboratory research and investigative purposes. These compounds are not approved by the FDA for human or veterinary use. They are not drugs, supplements, or medications. Lumen Peppers makes no therapeutic claims. Researchers are solely responsible for ensuring compliance with all applicable laws and regulations in their jurisdiction.